JP2018505146A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505146A5
JP2018505146A5 JP2017533789A JP2017533789A JP2018505146A5 JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5 JP 2017533789 A JP2017533789 A JP 2017533789A JP 2017533789 A JP2017533789 A JP 2017533789A JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5
Authority
JP
Japan
Prior art keywords
amino
ethoxy
chem
acetyl
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505146A (ja
JP6727210B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080969 external-priority patent/WO2016102562A1/en
Publication of JP2018505146A publication Critical patent/JP2018505146A/ja
Publication of JP2018505146A5 publication Critical patent/JP2018505146A5/ja
Application granted granted Critical
Publication of JP6727210B2 publication Critical patent/JP6727210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533789A 2014-12-23 2015-12-22 Fgf21誘導体及びその使用 Active JP6727210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505146A JP2018505146A (ja) 2018-02-22
JP2018505146A5 true JP2018505146A5 (cg-RX-API-DMAC7.html) 2018-11-29
JP6727210B2 JP6727210B2 (ja) 2020-07-22

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533789A Active JP6727210B2 (ja) 2014-12-23 2015-12-22 Fgf21誘導体及びその使用

Country Status (24)

Country Link
US (3) US9744213B2 (cg-RX-API-DMAC7.html)
EP (1) EP3236991B1 (cg-RX-API-DMAC7.html)
JP (1) JP6727210B2 (cg-RX-API-DMAC7.html)
KR (1) KR102427527B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108709B (cg-RX-API-DMAC7.html)
AR (1) AR103246A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015371056B2 (cg-RX-API-DMAC7.html)
DK (1) DK3236991T3 (cg-RX-API-DMAC7.html)
ES (1) ES2742503T3 (cg-RX-API-DMAC7.html)
HK (1) HK1246156B (cg-RX-API-DMAC7.html)
HR (1) HRP20191292T1 (cg-RX-API-DMAC7.html)
HU (1) HUE044783T2 (cg-RX-API-DMAC7.html)
IL (1) IL252438B (cg-RX-API-DMAC7.html)
MX (1) MX377044B (cg-RX-API-DMAC7.html)
MY (1) MY181181A (cg-RX-API-DMAC7.html)
PL (1) PL3236991T3 (cg-RX-API-DMAC7.html)
PT (1) PT3236991T (cg-RX-API-DMAC7.html)
RS (1) RS59154B1 (cg-RX-API-DMAC7.html)
RU (1) RU2729011C2 (cg-RX-API-DMAC7.html)
SA (1) SA517381673B1 (cg-RX-API-DMAC7.html)
SI (1) SI3236991T1 (cg-RX-API-DMAC7.html)
TW (2) TWI708781B (cg-RX-API-DMAC7.html)
WO (1) WO2016102562A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703768B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190248852A1 (en) 2016-05-24 2019-08-15 Novo Nordisk A/S MIC-1 Compounds and Use Thereof
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
CN114601932A (zh) 2017-09-04 2022-06-10 89生物有限公司 突变型fgf-21肽缀合物及其用途
BR112020026512A2 (pt) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US20240239855A1 (en) 2021-05-11 2024-07-18 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
CN117586423A (zh) 2021-07-14 2024-02-23 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
CN116162145A (zh) * 2021-09-08 2023-05-26 北京志道生物科技有限公司 一种fgf21突变蛋白及其应用
TWI850016B (zh) * 2022-07-08 2024-07-21 丹麥商諾佛 儂迪克股份有限公司 能夠取代fviii(a)之高效isvd化合物
MA71385A (fr) 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
KR20250167609A (ko) 2023-03-30 2025-12-01 노보 노르디스크 에이/에스 융합 화합물 및 그 용도
TW202448921A (zh) * 2023-05-12 2024-12-16 丹麥商諾佛 儂迪克股份有限公司 長效生長激素受體拮抗劑及其用途
TW202511291A (zh) 2023-09-11 2025-03-16 丹麥商諾佛 儂迪克股份有限公司 抗il-6結構域之抗體
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
UA87458C2 (ru) 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
BRPI0416683A (pt) 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
DE602005016917D1 (de) 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
AU2005261740A1 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
EA011390B1 (ru) 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子21の突然変異タンパク質
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
SG195542A1 (en) * 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
ES2692495T3 (es) 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Fgf21変異体およびその使用
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
WO2013033452A2 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
BR112015004734A2 (pt) * 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
DK2938740T3 (da) * 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser

Similar Documents

Publication Publication Date Title
JP2018505146A5 (cg-RX-API-DMAC7.html)
RU2017125050A (ru) Производные fgf21 и их применения
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2013533227A5 (cg-RX-API-DMAC7.html)
JP2012529463A5 (cg-RX-API-DMAC7.html)
JP2011526886A5 (cg-RX-API-DMAC7.html)
JP2016512425A5 (cg-RX-API-DMAC7.html)
RU2011134454A (ru) Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение
JP2013543497A5 (cg-RX-API-DMAC7.html)
JP2017528419A5 (cg-RX-API-DMAC7.html)
HRP20191614T1 (hr) Spojevi koji su suagonisti gip i glp-1
JP2017502024A5 (cg-RX-API-DMAC7.html)
JP2017500289A5 (cg-RX-API-DMAC7.html)
JP2012506402A5 (cg-RX-API-DMAC7.html)
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
JP2016526012A5 (cg-RX-API-DMAC7.html)
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
JP2014224121A5 (cg-RX-API-DMAC7.html)
JP2016153410A5 (cg-RX-API-DMAC7.html)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
WO2011080102A3 (en) Glp-1 analogues and derivatives
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
NO20083793L (no) Antistoffer mot amyloid-beta peptid
WO2012069836A3 (en) Biologically active complex and its preparation
EP3980548A4 (en) Compositions useful for treatment of pompe disease